Protein microarray is an emerging technology that makes high-throughput analysis possible for protein-protein interactions and analysis of proteome and biomarkers in parallel. The authors investigated the application of a novel protein microarray chip, ProteoChip, in new drug discovery. Integrin α v β 3 microarray immobilized on the ProteoChip was employed to screen new active peptides against the integrin from multiple hexapeptide sublibraries of a positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin α v β 3 -vitronectin interaction was successfully demonstrated on the integrin microarray in a dose-dependent manner and was inhibited not only by the synthetic RGD peptide but also by various integrin antagonists on the integrin microarray chip. Novel peptide ligands with high affinity to the integrin were also identified from the peptide libraries with this chip-based screening system by a competitive inhibition assay in a simultaneous and highthroughput fashion. The authors have confirmed antiangiogenic functions of the novel peptides thus screened through an in vitro and in vivo angiogenesis assay. These results provide evidence that the ProteoChip is a promising tool for highthroughput screening of lead molecules in new drug development. (Journal of Biomolecular Screening 2004:687-694) 
INTRODUCTION
T HE GOALS OF PROTEOMICS RESEARCH are to establish molecular diagnostics that can detect multianalytes, target identification and validation, and screen new drug candidates. Currently, toolkits for proteomics research are 2-D gel electrophoresis and mass spectrometry for new protein discovery and analysis. 1, 2 However, they have limitations-in particular, difficulties in analyzing low-abundance, high-molecular weight, and hydrophobic proteins expressed in cells-and may not be properly applicable for high-throughput analysis of proteins. Because breakthrough technology for proteomics research is currently limited, array-based protein technologies, which provide high sensitivity and automation and can analyze thousands of proteins simultaneously in a single experiment and high-throughput fashion, are expected to be a promising tool for the further advancement of proteomics research. 3 Protein microarray allows us to analyze not only proteinprotein interactions (PPI) but also protein-small molecule interactions and protein-DNA interactions, providing important functional information for newly identified genes derived from the genome project. 4, 5 It has been recently reported that DNA-protein, 6 protein-protein, 7 receptor-ligand, 8, 9 and enzyme-substrate interactions [10] [11] [12] and transfected cells expressing different cDNAs 13 were analyzed by microarray-based assays. A recent work demonstrated that a protein microarray spotted with 5800 yeast proteins was able to determine protein-protein interactions, suggesting that array-based protein analysis could be used for proteomics research and protein-drug interactions. 14 A highly sensitive protein microarray is being rapidly developed as a core technology of the next generation for functional proteomics research, including studies of protein-protein interactions and protein expression profiling and methods for new lead screening. Array-based proteomics also promises to become a useful tool for parallel analyses of biomarkers, particularly in the assessment of immune response and drug interactions. 3, 15 We have developed ProteoChip, a highly sensitive protein microarray chip, which is coated with a bifunctional molecular linker, ProLinker ™ , on an aminated glass slide. 16, 17 The ProteoChip has been shown to be useful for the direct detection of proteinprotein and protein-small molecule interactions with high sensitivity, reproducibility, and accuracy and to be applicable for biomarker assays as well as new lead screening. In this article, it is reported that an integrin protein chip has been successfully prepared with the ProteoChip and applied for the high-throughput library screening of new active peptides against a specific integrin-ECM (integrin α v β 3 -vitronectin) interaction system from a positional scanning synthetic peptide combinatorial library (PS-SPCL). The biological activity of the hexapeptides with a new amino acid motif screened by the integrin chip was confirmed by methods of human umbilical vein endothelial (HUVE) cell migration and chick chorioallantoic membrane (CAM) assays.
MATERIALS AND METHODS

Proteins and peptides
Target proteins used in this article are integrin α v β 3 -vitronectin and integrin α IIb β 3 -fibrinogen systems. Integrin α IIb β 3 was purified to homogeneity by GRGDSPK-Sepharose column chromatography, 18 and integrin α v β 3 was purchased from Chemicon International, Inc. (Temecula, CA). The ECM proteins, vitronectin and fibrinogen, were obtained commercially from Chemicon International, Inc.
The PS-SPCL consisted of 114 hexapeptide mixtures with COOH-terminal amidation divided into 6 groups corresponding to each position within the hexapeptide. For each position, 19 mixtures (cysteine residue was excluded) were surveyed, each of which was defined by 1 of the 19 natural L-amino acids. The undefined positions were occupied by any of the L-amino acids, except cysteine. PS-SPCL was kindly donated from Pohang University of Science and Technology, Korea. All peptides used for the competitive inhibition assay were synthesized by Peptron, Inc. (Dajeon, Korea) and the Korea Research Institute of Bioscience and Biotechnology (KRIBB).
Integrin microarray printing
To fabricate protein microarrays, a high-precision contactprinting robotic arrayer (CM-1000; Proteogen, Inc., Seoul, Korea) equipped with Stealth Micro-spotting Pins (SMP10; TeleChem, Sunnyvale, CA) was used for delivering nanoliter volumes of integrins onto ProLinker ™ -coated glass slides (ProteoChip; Proteogen, Inc., Seoul, Korea), yielding spots of about 80 to 100 µm or 300 to 320 µm in diameter, respectively. Integrins (40 µg/ mL) diluted with a phosphate-buffered saline (PBS) solution containing 10 mM β-octylthioglucopyranoside, 1.0 mM CaCl 2 , 1.0 mM MgCl 2 , and 30% glycerol to prevent evaporation of the nanodroplets were spotted and incubated at 37°C for 3 h followed by washing with 0.5% PBST (PBS containing 0.5% Tween-20). The integrin microarray was stored at 4°C until before use.
Integrin-ECM interactions
Integrin microarrays were blocked with 3% bovine serum albumin (BSA) for 1 h and washed 3 times with 0.5% PBST. After the washing step, integrin microarrays were subsequently spotted with integrin ligands (fibrinogen for integrin α IIb β 3 and vitronectin for integrin α v β 3 ) ranging from 1.0 µg/mL to 1.0 fg/mL labeled with a fluorescent probe at 37°C for 1 h. Fluorescence intensities of each spot were measured by a fluorescence scanner.
Competitive inhibition assay
Integrin microarrays were blocked with 3% BSA for 1 h and washed 3 times with 0.5% PBST. After washing with PBST, integrin microarrays were subsequently incubated with a mixture of integrin ligands (250 ng/mL) labeled with a fluorescent probe and a sublibrary peptide pool (6.0 nM) from a hexapeptide library (PS-SPCL provided by Pohang University of Science and Technology) at 37°C for 1 h. The hexapeptide library has 114 sublibrary peptide pools that have approximately 2.5 million different peptide sequences. Fluorescence intensities of the spots on the integrin chip were detected by a fluorescence laser scanner after washing 3 times with PBST. Competitive inhibitors are determined by measuring relative fluorescence intensities between each peptide spot and control peptides (GRGDSP and GRGESP).
Fluorescence scanning analysis
The ProteoChip arrays thus prepared for protein immobilization and protein-protein interaction were scanned in a ScanArray Lite model (GSI Lumonics, Inc., Ottawa, Canada) scanner using 532-nm or 635-nm lasers. The numerical values of bound proteins were determined by the fluorescence intensity of each spot on the array by software installed in the fluorescence scanner. The location of each analyte spot on the array was outlined using the gridding software ImaGene (BioDiscovery, Inc., El Segundo, CA).
HUVE cell migration assay
Cell migration assays were performed in a modified Boyden chamber (48-well chemotaxis chamber AP48; Neuro Probe, Gaithersburg, MD). Polycarbonate membranes (8-µm pore, 25 × 80-mm size, polyvinylpyrrolidine free; Neuro Probe) were coated with 100 µg/mL of denatured collagen in PBS. Basic FGF (10 ng/ mL) was added to EBM-2 in the bottom chamber, and cells suspended in the medium with the indicated concentration of synthetic peptides for 30 min and 1 × 10 4 cells in 50 µL were added to the upper chamber of each well. The chamber was incubated for 6 h at 37°C with 5% CO 2 to allow cells to migrate through the denatured collagen-coated polycarbonate membrane. Nonmigrating cells on the upper surface of the membrane were removed with a wiper tool (Neuro Probe), and then the membrane was stained with Diff-Quik (VWR Scientific Products, Bridgeport, NJ). The total number of cells with nuclei that migrated per well was determined as described. 19 The data were evaluated as relative cell migration, which is the percentage compared with the mean cell number for the medium containing only BSA. The assays were performed in quadruplicate.
Basic FGF-induced CAM angiogenesis assay
To determine antiangiogenic activity in vivo, the CAM assay was performed as previously described. 20, 21 Fertilized eggs were incubated at 37°C in humidified air. Ovalbumin (4-5 mL) was extracted at the bottom of the eggs using a syringe on day 3, and windows were made within the top of the eggs. The windows were sealed with transparent tape, and the eggs were further incubated until day 9. Thermanox (Nunc, Naperville, IL) coverslips containing basic FGF (bFGF, 10 ng) or bFGF plus peptides were implanted on the CAM of the individual embryo. After a 48-h incubation, intralipose (white fat emulsion solution) was injected into the CAM for distinct discrimination of the blood vessel formation, and CAMs were observed under a microscope and then photographed.
RESULTS
Integrin microarray on the ProteoChip
The integrin microarray was subjected for direct analysis of an integrin-ECM interaction and for the screening of peptide antagonists with high binding affinity to the integrin receptor from PS-SPCL. To construct integrin microarrays, integrin α IIb β 3 and integrin α v β 3 were immobilized as capture proteins on the ProteoChip. Nanoliter volumes of the integrin in PBS containing a detergent, β-octylthioglucopyranoside, were spotted on a ProteoChip base plate with a microarrayer. The saturated concentration of the integrin immobilized on the chip was 10 µg/mL. The integrin α IIb β 3 and α v β 3 microarrays were then incubated with fluorescence-labeled ligands, such as fibrinogen for integrin α IIb β 3 and vitronectin for integrin α v β 3 in different concentrations ranging from 1.0 µg/mL to 1.0 fg/mL. After washing, fluorescence intensities were detected for each spot with a laser fluorescence scanner. As shown in Figure 1A , it is shown that the ECM proteins were bound to the corresponding integrin system and that there was an inverse linear relationship between the relative fluorescence intensities of the bound protein as a function of the ligand concentrations ( Fig. 1B) . Detection limits of fibrinogen and vitronectin were observed at a ligand concentration of 1.0 fg/mL and 1.0 pg/mL, respectively. These findings indicated that the integrin-ligand interaction occurred on the surface of the ProteoChip without any functional changes of the receptor molecules.
Competitive inhibition of integrin-ECM interactions by integrin antagonists
To examine whether the integrin microarray can be used for the screening of integrin antagonists, we tested the competitive inhibition of the integrin-ligand interaction with well-known integrin antagonists. In this experiment, the integrin α v β 3 -vitronectin system was used. This integrin was immobilized as capture proteins on the ProteoChip, and then the fluorescence-labeled ECMs were applied with either GRGDSP peptide or GRGESP peptide on the integrin microarrays. The RGD peptide, a known antagonistic peptide against the integrin receptor, inhibited the integrin α v β 3vitronectin interaction significantly in a dose-dependent manner, whereas the RGD peptide showed little inhibitory effect on the interaction ( Fig. 2A, B ). Half-maximal inhibitions of integrin α v β 3vitronectin interactions by the RGD peptide were determined to be 2.44 × 10 -3 ng/mL. Several other integrin antagonists, such as 4 different snake venom-derived disintegrins (e.g., flavoridin, echistatin, kistrin, and salmosin), also suppressed the integrin α v β 3 -vitronectin interaction, as shown in Figure 2C -F. Half-maximal inhibitions of integrin α v β 3 -vitronectin interactions by 4 disintegrinsflavoridin, echistatin, kistrin, and salmosin-were determined to be 7.19 × 10 -3 ng/mL, 1.06 × 10 -2 ng/mL, 3.88 × 10 -3 ng/mL, and 4.74 × 10 -3 ng/mL, respectively. These results strongly suggest that the integrin microarray chip should be possible to screen affinity ligands specific to an integrin receptor.
HTS of Novel Peptide Inhibitors Using a Protein Microarray Chip
High-throughput screening of peptide inhibitors of integrin receptors from PS-SPCL using the integrin microarray
To assess whether the integrin microarray is capable of performing high-throughput screening (HTS) of high-affinity ligands for an integrin-ECM interaction system from PS-SPCL, we carried out a competitive inhibition assay using the integrin α v β 3 microarray. An integrin chip with 476 array spots of the integrin receptor was designed and prepared with an automatic microarrayer, CM-1000 (Proteogen, Inc., Seoul, Korea), to screen antagonistic peptides on a single microchip (Fig. 3A) . Fluorescence-labeled vitronectin was then applied to the integrin microarray in the presence of 114 hexapeptide sublibrary pools (Fig. 3B ). Green and blue spots indicate peptides that inhibited the integrin α v β 3vitronectin interaction, but white and yellow spots show a little or no inhibition. Open rectangles with white and red color on the microarray spots reveal the sublibrary pools with antagonistic pep-tides against the integrin α v β 3 -vitronectin interaction system (Fig.  3B ). The red rectangles may be more potent peptides, whereas the white ones may be less effective inhibitory ligands.
From the inhibition state of 114 sublibrary spots, in which 1 out of 6 amino acids of the hexapeptide libraries was positioned, the hexapeptide sublibrary pools with the designated amino acid at the given positions were identified (Fig. 4) . It was identified that 5 or 10 amino acids showed inhibitory effects at the position 5 or 6 of hexapeptide sequences, respectively. This implies that the amino acids at positions 5 and 6 of hexapeptides may not be compulsory as a binding motif to the integrin α v β 3 and vitronectin interface. However, at least 2 amino acids at the position from 2 to 4 of the hexapeptides were identified to exert a strong inhibitory effect on the integrin system, although there were minor effects by hexapeptides with 4, 3, and 2 amino acids at positions 2, 3, and 4, respectively ( Fig. 4 ). Based on the information obtained from the hexapeptide library screening, Gly/Ser/His, Leu/Asp, and Leu/Val were chosen for the amino acids at positions 2, 3, and 4, respectively. In addition, His for positions 1 and 5 and Lys for position 6 were fixed. The result suggests that there may be conserved amino acid motifs at the given sequence positions of the hexapeptide libraries for the inhibitory effect of the integrin system we have tested. From the inhibitory effect of the hexapeptide sublibraries with a known amino acid at a given position, it is possible to predict active peptide sequences, which are expected to exhibit an antagonistic effect against the integrin α v β 3 -vitronectin system. The 12 active peptide sequences were identified by combinations of the potent amino acids (Gly/Ser/His, Leu/Asp, and Leu/Val) as de- scribed above at the 3 different positions (positions 2, 3, and 4) of the hexapeptide sublibraries that showed major inhibitory effects on the integrin α v β 3 -vitronectin system.
Secondary screening of the inhibitory effect of synthetic hexapeptides with active sequences
To confirm the inhibitory activity of the hexapeptides identified from the above screening procedure with the integrin microarray, 12 peptide sequences predicted in Figure 4 were synthesized and subjected to a test for the competitive inhibition assay against the integrin α v β 3 -vitronectin system in a dose-dependent manner (Table 1). Seven synthetic hexapeptides, including HHLLHK, HGLVHK, and HSDVHK, inhibited significantly the integrin α v β 3 -vitronectin interaction in a dose-dependent manner. However, peptides 1, 2, 5, 6, and 12 revealed weak or no inhibition on the integrin α v β 3 -vitronectin interaction. Half-maximal inhibitions of the integrin α v β 3 -vitronectin interaction by HSDVHK, HHLLHK, HGLVHK, HGDLHK, and HGDVHK were observed at concentrations of approximately 1.74, 3.45, 2.43, 30.7, and 44.7 pg/mL, respectively (Table 1) . Among the 12 antagonistic hexapeptides, HSDVHK appears to be the most effective in suppressing the interaction compared with the other hexapeptides. These sequences are shown to be new binding motifs with a high affinity to integrin α v β 3 in addition to the RGD sequence, which is a well-known and potent binding motif for integrin receptors. Interestingly, Gly-Leu-Val (GLV), Ser-Asp-Val (SDV), His-Leu-Leu (HLL), Gly-Asp-Leu (GDL), and Gly-Asp-Val (GDV) se- quences of antagonistic peptides bound to integrin α v β 3 had not been reported yet. Our data revealed that these motifs were able to inhibit direct interaction of integrin α v β 3 with vitronectin on the integrin microarray chip.
Biological characterization of the novel peptide inhibitors
To determine biological activities of the antagonistic peptides against integrin α v β 3 , we carried out an in vitro and in vivo angiogenesis assay. In an HUVE cell migration assay in vitro, HGDVHK and HSDVHK significantly inhibited bFGF-induced cell migration compared to the PBS control group, whereas other synthetic peptides had a little or no effect on cell migration (Fig.  5A) . The inhibitory effects of 2 peptides were shown to be dose dependent ( Fig. 5B) . To investigate the inhibition of angiogenesis in vivo by the antagonistic peptides, we employed a bFGF-induced CAM angiogenesis assay. We applied 10 µg of peptides showing an inhibitory effect on HUVEC migration on a chick embryo and examined the inhibitory effect of new blood vessel formation in chick CAM. HGDVHK and HSDVHK also suppressed bFGFinduced chick CAM angiogenesis compared to the PBS control group, whereas HHDVHK appeared to have weak inhibition on the CAM angiogenesis. Synthetic RGD peptide (GRGDSP) also inhibited the angiogenesis in vivo (Fig. 6 ).
DISCUSSION
Protein microarrays have been used for the global analysis of protein-protein interactions. 12, 14 However, few practical experimental data have been reported for the HTS of lead molecules in new drug development using a protein microarray chip. In this report, we carried out proof-of-concept experiments for the HTS of lead molecules for new drug discovery using the integrin microarray prepared with the ProteoChip and demonstrated that the protein microarray chip was a promising tool for the HTS of new lead molecules. The present report on an alternative approach for new peptide inhibitor screening by using an integrin chip provides evidence for the practical applicability of several important breakthrough technologies, such as (1) the preparation of a protein microarray chip for receptor proteins such as integrins, (2) applications of high-throughput chip-based lead screening by using a protein-protein interaction system as a drug target, and (3) rapid identification of affinity peptide sequences from PS-SPCL via protein microarrays.
There are several advantages in using the ProteoChip for library screening over the conventional assay system. First, the ProteoChip is useful for the efficient immobilization of membrane receptor proteins, such as integrins, on solid chip surfaces. The successful preparation of the integrin chip can be attributed to the unique and distinct surface properties of the ProteoChip provided by ProLinker ™ . ProLinker ™ A and B, calixcrown-5 derivatives, are novel bifunctional molecular linkers, which have a crown moiety for protein binding and a thiol or aldehyde group for the formation of a self-assembled monolayer on solid substrates for efficient protein immobilization on solid surfaces. ProLinker ™ A, containing aldehyde groups, is used for aminated glass to make ProteoChip A, which can be used for the analysis of fluorescence-probed proteins with a fluorescence scanner. ProLinker ™ B, containing thiol groups, is used for gold-coated glass to prepare ProteoChip B, which can be used for protein analysis via an SPR or QCM system without probing analyte proteins. Proteins arrayed on a ProteoChip base plate can be bound tightly, forming a high-density protein layer without their activity loss and, with the right orienta- tion, allowing ligand proteins to interact properly. The binding mechanism of integrin receptor molecules could be attributed to (1) the host-guest interaction of the amine group of proteins and the crown moiety of ProLinker ™ and (2) the hydrophobic interaction between hydrophobic side chains and the methoxyl group of the linker molecule. 17 On the basis of the unique surface characteristics of the integrin chip, it was possible to apply it successfully for the screening of new peptide inhibitors specific to integrin α v β 3 in an amino acid sequence-dependent manner. Second, ProteoChip allows us to prepare a medium-to highdensity integrin microarray on the chip surface with a microarrayer. It is thus possible to use the integrin microarray for the efficient screening of integrin-specific ligands in a high-throughput fashion. It is, however, recommended that a minute size of a spot should be avoided to keep a proper volume of the protein solution for binding reactions on a spot. In this experiment, we have successfully prepared a medium-density microarray with 476 spots spotted with a 300-µm pin on a ProteoChip base plate for the screening of hexapeptide libraries. It is, however, possible to apply about 1000 spot microarrays on a base plate when dealing with a large number of compound libraries.
Third, the application volume of the microarray spots is about 20 to 30 nL, and it requires about a nanogram level of proteins. The small amount of protein and reagent consumption makes the chipbased screening system highly cost-effective in comparison with the conventional plate-based screening system, which requires microliter and microgram levels of expensive proteins and reagents. Finally, an easy-to-use protocol to make the protein microarray provides a simple and reproducible technique for analyzing protein interactions. The process constructing the protein microarray consists of spotting, washing, and reading out in a scanner.
In general, the active peptide sequences have been identified from the active motif of the binding domain of the interacting pro-teins, which is laborious and time-consuming. In particular, there has been no way to identify the active amino acid sequences specific to a protein-protein interaction system from a 2.5-million sequence pool of peptide libraries. Several methods have been reported for the rapid identification of affinity ligand peptides from PS-SPCL via a spatially addressable array using a microplate system 22 and bead-based analytical systems. 23, 24 However, the application of a protein microarray for the screening of peptide libraries has made it possible to identify active peptide sequences more rapidly and conveniently from sublibrary pools of the PS-SPCL. FIG. 6. Inhibitory effect of integrin α v β 3 antagonistic peptides on in vivo angiogenesis in a chick chorioallantoic membrane (CAM). To the CAM surfaces, 10-µg samples and basic FGF (bFGF) were added, and then the eggs were incubated for 48 h as described under Materials and Methods. Samples produced a vascular zone. The antiangiogenic activity was assessed as described under Materials and Methods. Combined results from 3 independent assays are shown, and each experiment contained approximately 10 eggs/sample. Angiogenesis in CAM was measured. Arrows reveal the CAM areas that were implanted with a sterile thick cellulose disc (Thermanox, Nunc) loaded with samples.
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The overall procedures of active peptide screening from peptide libraries for a particular protein-protein interaction system can be summarized as follows:
1. primary screening of sublibrary pools with active peptides from PS-SPCL with the ProteoChip, 2. identification of active sequences from the inhibitory patterns on array spots of sublibrary pools with a known amino acid at a given position, 3. preparation of synthetic peptides with active sequences predicted, 4. secondary screening of inhibitory activities of the synthetic peptides with the ProteoChip, 5. confirmation of the inhibitory activity with in vitro and in vivo biological tests.
In conclusion, the results demonstrated in this report provide firm evidence that the ProteoChip-based screening system will be a breakthrough technology in new drug discovery. The present screening system is also advantage over existing screening systems because it only requires a nanoliter or a nanogram level of proteins and compound libraries for a spot, and it is possible to reduce screening costs and time by a high-throughput approach. We have developed the ProteoChip-based lead screening system for the identification of antagonistic peptides against integrin α v β 3 from the hexapeptide library.
